Hematologic Malignancies: Where Do We Stand in 2011?

Major advances in understanding the biology of hematologic malignancies and the development of new therapies are occurring at a rapid pace, and Journal of Clinical Oncology (JCO) is committed to offering the oncology community and oncology experts the most up-to-date information pertinent to our research and practice. In this context, it became clear that an issue of JCO dedicated to updating the pathophysiology, molecular pathogenesis, and therapies of leukemias and myelodysplastic syndrome (MDS) would be valuable